Single nucleotide polymorphisms in antigen processing machinery component ERAPI significantly associate with clinical outcome in cervical carcinoma

Genes Chromosomes and Cancer

Volumn 48, Issue 5, 2009, Pages 410-418

  Mehta, Akash M ^a,b   Jordanova, Ekaterina S ^a   Corver, Willem E ^a   Ven Wezel, Tom ^a   Uh, Hae Won ^a   Kenter, Gemma G ^a   Fleuren, Gert Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Kennemer Gasthuis ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; AMINOPEPTIDASE; ARTS 1 PROTEIN, HUMAN; ARTS-1 PROTEIN, HUMAN;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; CANCER RISK; CANCER STAGING; CARCINOGENESIS; ERAP I GENE; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GROWTH; TUMOR VOLUME; UTERINE CERVIX CARCINOMA; CHI SQUARE DISTRIBUTION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK; UTERINE CERVIX TUMOR;

ADULT; AGED; AGED, 80 AND OVER; AMINOPEPTIDASES; CHI-SQUARE DISTRIBUTION; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK; UTERINE CERVICAL NEOPLASMS;

EID: 65349123542     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20648     Document Type: Article

References (52)

1. Albiston AL, Ye S, Chai SY. 2004. Membrane bound members of the M1 family: More than aminopeptidases. Protein Pept Lett 11:491-500.
2. Becker T, Knapp M. 2004. A powerful strategy to account for multiple testing in the context of haplotype analysis. Am J Hum Genet 75:561-570.
3. Becker T, Cichon S, Jonson E, Knapp M. 2005a. Multiple testing in the context of haplotype analysis revisited: Application to case-control data. Ann Hum Genet 69:747-756.
4. Becker T, Schumacher J, Cichon S, Baur MP, Knapp M. 2005b. Haplotype interaction analysis of unlinked regions. Genet Epidemiol 29:313-322.
5. Brady CS, Bartholomew JS, Burt DJ, Duggan-Keen MF, Glenville S, Telford N, Little AM, Davidson JA, Jimenez P, Ruiz-Cabello F, Garrido F, Stern PL. 2000. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 55:401-411.
6. Cao B, Tian X, Li Y, Jiang P, Ning T, Xing H, Zhao Y, Zhang C, Shi X, Chen D, Shen Y, Ke Y. 2005. LMP7/TAP2 gene polymorphisms and HPV infection in esophageal carcinoma patients from a high incidence area in China. Carcinogenesis 26:1280-1284.
7. Casp CB, She JX, McCormack WT. 2003. Genes of the LMP/TAP cluster are associated with the human autoimmune disease vitiligo. Genes Immun 4:492-499.
8. Chang SC, Momburg F, Bhutani N, Goldberg AL. 2005. The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a ''molecular ruler'' mechanism. Proc Natl Acad Sci USA 102:17107-17112.
9. Corver WE, Ter Haar NT, Dreef EJ, Miranda NF, Prins FA, Jordanova ES, Cornelisse CJ, Fleuren GJ. 2005. High-resolution multi-parameter DNA flow cytometry enables detection of tumour and stromal cell subpopulations in paraffin-embedded tissues. J Pathol 206:233-241.
10. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJ, Walboomers JM. 1994a. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 179:335-340.
11. Cromme FV, van Bommel PF, Walboomers JM, Gallee MP, Stern PL, Kenemans P, Helmerhorst TJ, Stukart MJ, Meijer CJ. 1994b. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 69:1176-1181.
12. Daniel S, Caillat-Zucman S, Hammer J, Bach JF, van Endert PM. 1997. Absence of functional relevance of human transporter associated with antigen processing polymorphism for peptide selection. J Immunol 159:2350-2357.
13. de Boer MA, Jordanova ES, Kenter GG, Peters AA, Corver WE, Trimbos JB, Fleuren GJ. 2007. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. Clin Cancer Res 13:132-138.
14. Facoetti A, Nano R, Zelini P, Morbini P, Benericetti E, Ceroni M, Campoli M, Ferrone S. 2005. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res 11:8304-8311.
15. Falk K, Rotzschke O. 2002. The final cut: How ERAP1 trims MHC ligands to size. Nat Immunol 3:1121-1122.
16. Fowler NL, Frazer IH. 2004. Mutations in TAP genes are common in cervical carcinomas. Gynecol Oncol 92:914-921.
17. Gostout BS, Poland GA, Calhoun ES, Sohni YR, Giuntoli RL, McGovern RM, Sloan JA, Cha SS, Persing DH. 2003. TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol Oncol 88:326-332.
18. Gromme M, Neefjes J. 2002. Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol 39:181-202.
19. Hammer GE, Gonzalez F, Champsaur M, Cado D, Shastri N. 2006. The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat Immunol 7:103-112.
20. Heemels MT, Ploegh H. 1995. Generation, translocation, and presentation of MHC class I-restricted peptides. Annu Rev Biochem 64:463-491.
21. Hilders CG, Houbiers JG, Krul EJ, Fleuren GJ. 1994. The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma. Am J Clin Pathol 101:5-12.
22. Hilders CG, Munoz IM, Nooyen Y, Fleuren GJ. 1995. Altered HLA expression by metastaic cervical carcinoma cells as a factor in impaired immune surveillance. Gynecol Oncol 57:366-375.
23. Josefsson A, Livak K, Gyllensten U. 1999. Detection and quantitation of human papilomavirus by using the fluorescent 5′ exonuclease assay. J Clin Microbiol 37:490-496.
24. Keating PJ, Cromme FV, Duggan-Keen M, Snijders PJ, Walboomers JM, Hunter RD, Dyer PA, Stern PL. 1995. Frequency of downregulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 72:405-411.
25. Lankat-Buttgereit B, Tampe R. 2002. The transporter associated with antigen processing: Function and implications in human diseases. Physiol Rev 82:187-204.
26. ' nuclease assay. Genet Anal 14:143-149.
27. Magnusson PK, Sparen P, Gyllensten UB. 1999. Genetic link to cervical tumours. Nature 400:29-30.
28. McCluskey J, Rossjohn J, Purcell AW. 2004. TAP genes and immunity. Curr Opin Immunol 16:651-659.
29. Mehta AM, Jordanova ES, van Wezel T, Uh HW, Corver WE, Kwappenberg KM, Verduijn W, Kenter GG, van der Burg SH, Fleuren GJ. 2007. Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes Chromosomes Cancer 46:577-586.
30. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren G. 2008. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57:197-206.
31. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B. 2005. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: Association with clinical outcome. Clin Cancer Res 11:2552-2560.
32. Mishto M, Bellavista E, Santoro A, Stolzing A, Ligorio C, Nacmias B, Spazzafumo L, Chiappelli M, Licastro F, Sorbi S, Pession A, Ohm T, Grune T, Franceschi C. 2006. Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiol Aging 27:54-66.
33. Neefjes J, Gottfried E, Roelse J, Gromme M, Obst R, Hammerling GJ, Momburg F. 1995. Analysis of the fine specificity of rat, mouse and human TAP peptide transporters. Eur J Immunol 25:1133-1136.
34. Niesporek S, Meyer CG, Kremsner PG, May J. 2005. Polymorphisms of transporter associated with antigen processing type 1 (TAP1), proteasome subunit beta type 9 (PSMB9) and their common promoter in African children with different manifestations of malaria. Int J Immunogenet 32:7-11.
35. Obst R, Armandola EA, Nijenhuis M, Momburg F, Hammerling GJ. 1995. TAP polymorphism does not influence transport of peptide variants in mice and humans. Eur J Immunol 25:2170-2176.
36. Powis SH, Tonks S, Mockridge I, Kelly AP, Bodmer JG, Trowsdale J. 1993. Alleles and haplotypes of the MHC-encoded ABC transporters TAP1 and TAP2. Immunogenetics 37:373-380.
37. Quadri SA, Singal DP. 1998. Peptide transport in human lymphoblastoid and tumor cells: Effect of transporter associated with antigen presentation (TAP) polymorphism. Immunol Lett 61:25-31.
38. Rawlings ND, Barrett AJ. 1995. Evolutionary families of metallopeptidases. Methods Enzymol 248:183-228.
39. Ritz U, Seliger B. 2001. The transporter associated with antigen processing (TAP): Structural integrity, expression, function, and its clinical relevance. Mol Med 7:149-158.
40. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B. 2001. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 19:1211-1220.
41. Saric T, Chang SC, Hattori A, York IA, Markant S, Rock KL, Tsujimoto M, Goldberg AL. 2002. An IFN-gammainduced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol 3:1169-1176.
42. Sasieni PD. 1997. From genotypes to genes: Doubling the sample size. Biometrics 53:1253-1261.
43. Saveanu L, Carroll O, Lindo V, Del Val M, Lopez D, Lepelletier Y, Greer F, Schomburg L, Fruci D, Niedermann G, van Endert PM. 2005. Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat Immunol 6:689-697.
44. Seliger B, Ritz U, Ferrone S. 2006. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 118:129-138.
45. Sugimoto Y, Kuzushita N, Takehara T, Kanto T, Tatsumi T, Miyagi T, Jinushi M, Ohkawa K, Horimoto M, Kasahara A, Hori M, Sasaki Y, Hayashi N. 2002. A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. J Viral Hepat 9:377-384.
46. van Driel WJ, Tjiong MY, Hilders CG, Trimbos BJ, Fleuren GJ. 1996. Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma. Gynecol Oncol 62:33-41.
47. Van Kaer L. 2002. Major histocompatibility complex class I-restricted antigen processing and presentation. Tissue Antigens 60:1-9.
48. Vargas-Alarcon G, Gamboa R, Zuniga J, Fragoso JM, Hernandez-Pacheco G, Londono J, Pacheco-Tena C, Cardiel MH, Granados J, Burgos-Vargas R. 2004. Association study of LMP gene polymorphisms in Mexican patients with spondyloarthritis. Hum Immunol 65:1437-1442.
49. Yamamoto N, Nakayama J, Yamakawa-Kobayashi K, Hamaguchi H, Miyazaki R, Arinami T. 2002. Identification of 33 polymorphisms in the adipocyte-derived leucine aminopeptidase (ALAP) gene and possible association with hypertension. Hum Mutat 19:251-257.
50. Yan J, Parekh VV, Mendez-Fernandez Y, Olivares-Villagomez D, Dragovic S, Hill T, Roopenian DC, Joyce S, Van Kaer L. 2006. In vivo role of ER-associated peptidase activity in tailoring peptides for presentation by MHC class Ia and class Ib molecules. J Exp Med 203:647-659.
51. York IA, Rock KL. 1996. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14:369-396.
52. York IA, Chang SC, Saric T, Keys JA, Favreau JM, Goldberg AL, Rock KL. 2002. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat Immunol 3:1177-1184.